secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010508
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down
--------------------------------------------------------------------------------

- Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.
- ROCTAVIAN asset write-down of ~$230-260M in Q4 2025; $0.60-$0.64 non-GAAP EPS impact.
- Excluding write-down, previous FY2025 non-GAAP EPS guidance unchanged.
- Approximately 200M weighted-average diluted shares outstanding assumed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/0001193125-26-010508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer